Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease

Overview

REVASC is a randomized, double-blind, placebo-controlled study which will involve 150 patients with chronic bronchitis and COPD diagnosed cardiovascular disease. The recruitment period beginimg in the coming weeks, will last nine months. Patients included in the study will receive treatment for three months with roflumilast 500 mg (75 patients) or placebo (75 patients) in a randomized manner. The CIBERES, as promoter of this study is expected to release final results for the third quarter of 2013. Eight centers in Madrid will be involved in this clinical trial: Fundación Jiménez Díaz, Hospital La Princesa, Hospital Gregorio Maranon Hospital Clinico San Carlos, Hospital La Paz, Hospital Ramón y Cajal Hospital Doce de Octubre and Hospital Puerta del Hierro. Roflumilast is a potent phosphodiesterase-4 inhibitor (PDE4). Its clinical efficacy has been studied in an extensive clinical program involving over 12,000 patients with COPD. In these studies, roflumilast (in combination with long-acting bronchodilators) reduced the number of exacerbations and improved lung function, especially in those patients with associated chronic bronchitis.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: July 2012

Interventions

  • Drug: Roflumilast 500
    • Roflumilast 500 mcg , 12 weeks of treatment
  • Drug: Placebo
    • Placebo 500 mcg , 12 weeks of treatment

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo
  • Active Comparator: Roflumilast
    • Roflumilast 500 mcg

Clinical Trial Outcome Measures

Primary Measures

  • Endotelial function
    • Time Frame: 12 weeks

Secondary Measures

  • Arterial siffness
    • Time Frame: 12 weeks
  • Serum and plasma inflammation markers: (CRP, fibrinogen, leucocytes, interleukin (IL)-8, IL-6, IL-10, tumor necrosis factor alpha (TNFα), sICAM-1, MCP-1, PARC/CCL-18)
    • Time Frame: 12 weeks
  • Serum oxidatrive stress markers: MPO, TRX
    • Time Frame: 12 weeks
  • Serum endothelial dysfunction markers:TWEAKs, FasL, ADMA
    • Time Frame: 12 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Signed informed consent – 55-75 years of age – Current and former smokers >20 cigarettes pack-yr (if former smokers withdrawn >1 year) – Diagnosis COPD (GOLD criteria1 for more than a year before V0) – Presence of chronic bronchitis (cough and/or expectoration for more that 3 months/yr for more than 2 consecutive yrs. in the absence of other potential cause) – Post-bronchodilator FEV1<70% reference – Presence of established CVD, CVD equivalent or diabetes mellitus – Presence of chronic systemic inflammation, determined on: 1. Serum CRP ≥ 2 and < 10 mg/l or 2. Serum fibrinogen > 518 mg/dl and Leucocytes > 8,6*106 /mm3 Exclusion Criteria:

  • Episode of COPD exacerbation and/or COPD treatment change during the last 2 months before V0 – History of asthma, significant residual lung lesions or bronchiectasis on chest x-ray – Apnea-hypopnea syndrome – Poorly controlled CVD risk factors (Table 2) and/or change in their treatment during the last 3 months before V0 – Clinically significant cardiac arrhythmias or valve disease – Severe concomitant immunological, inflammatory, infectious or neoplastic diseases – Moderate or severe hepatic insufficiency (B or C class, following Child-Pugh scale) – Severe neurologic and/or psychiatric disorder, including depression with suicidal ideas – Alcohol and/or drug abuse during the last 12 months before V0 – Hypersensitivity to roflumilast or to any of its excipients – Pregnancy or potential pregnancy – Participation in other clinical trial during the last 30 days before V0 – Language difficulties to follow the instructions of the study

Gender Eligibility: All

Minimum Age: 55 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Spanish Research Center for Respiratory Diseases
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Julio Ancochea, Principal Investigator, Hospital Universitario La Princesa
    • Carlos Álvarez, Principal Investigator, Hospital Universitario Doce de Octubre
    • Pilar De Lucas, Principal Investigator, Hospital General Universitario Gregorio Marañón
    • Myriam Calle, Principal Investigator, Hospital Clínico Universitario San Carlos
    • Salvador Díaz, Principal Investigator, Hospital Universitario Ramón y Cajal
    • Francisco García, Principal Investigator, Hospital Universitario La Paz
    • Rosa Malo, Principal Investigator, Hospital Universitario Puerta de Hierro
    • Germán Peces-Barba, Principal Investigator, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
  • Overall Contact(s)
    • Àlvar Agustí, 971 011 772, info@ciberes.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.